Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
DS-1103a is an antibody that targets SIRPA and prevents its interaction with CD47, which potentially enhances macrophage-dependent anti-tumor activity (Journal for ImmunoTherapy of Cancer 2022, Vol 10: Suppl 2, 808).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|DS-1103a + Trastuzumab deruxtecan||DS-1103a Trastuzumab deruxtecan||0||1|